Shun Shimohama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shun Shimohama has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Takashi Taniguchi
5 shared publicationsKengo Uemura
Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4 shared publicationsNaoyuki Kitagawa
Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4 shared publicationsRyuichi Kohno
Department of Neurology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyoku, Kyoto 606-8507, Japan
4 shared publicationsSadaki Fujimoto
Department of Environmental Biochemistry, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan
4 shared publicationsHiroko Tanino
Department of Environmental Biochemistry, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan
3 shared publications
Latest Publications
- 30 October 2006
- Published by Wiley in Journal of Neuroscience Research
- Vol. 85 (1) , 153-165
Presenilin 1 is involved in the maturation of β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1)
One of the pathologic hallmarks of Alzheimer's disease is the excessive deposition of β-amyloid peptides (Aβ) in senile plaques. Aβ is generated when β-amyloid precursor protein (APP) is cleaved sequentially by β-secretase, identified as β-site APP-cleaving enzyme 1 (BACE1), and γ-secretase, a putative enzymatic complex containing presenilin 1 (PS1). However, functional interaction between PS1 and BACE1 has never been known. In addition to this classical role in the generation of Aβ peptides, it has also been proposed that PS1 affects the intracellular trafficking and maturation of selected membrane proteins. We show that the levels of exogenous and endogenous mature BACE1 expressed in presenilin-deficient mouse embryonic fibroblasts (PS−/−MEFs) were reduced significantly compared to those in wild-type MEFs. Moreover, the levels of mature BACE1 were increased in human neuroblastoma cell line, SH-SY5Y, stably expressing wild-type PS1, compared to native cells. Conversely, the maturation of BACE1 was compromised under the stable expression of dominant–negative mutant PS1 overexpression. Immunoprecipitation assay showed that PS1 preferably interacts with proBACE1 rather than mature BACE1, indicating that PS1 can be directly involved in the maturation process of BACE1. Further, endogenous PS1 was immunoprecipitated with endogenous BACE1 in SH-SY5Y cells and mouse brain tissue. We conclude that PS1 is directly involved in the maturation of BACE1, thus possibly functioning as a regulator of both β- and γ-secretase in Aβ generation.
- 30 October 2006
- Published by Wiley in Journal of Neuroscience Research
- Vol. 85 (1) , 153-165
Presenilin 1 is involved in the maturation of β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1)
One of the pathologic hallmarks of Alzheimer's disease is the excessive deposition of β-amyloid peptides (Aβ) in senile plaques. Aβ is generated when β-amyloid precursor protein (APP) is cleaved sequentially by β-secretase, identified as β-site APP-cleaving enzyme 1 (BACE1), and γ-secretase, a putative enzymatic complex containing presenilin 1 (PS1). However, functional interaction between PS1 and BACE1 has never been known. In addition to this classical role in the generation of Aβ peptides, it has also been proposed that PS1 affects the intracellular trafficking and maturation of selected membrane proteins. We show that the levels of exogenous and endogenous mature BACE1 expressed in presenilin-deficient mouse embryonic fibroblasts (PS−/−MEFs) were reduced significantly compared to those in wild-type MEFs. Moreover, the levels of mature BACE1 were increased in human neuroblastoma cell line, SH-SY5Y, stably expressing wild-type PS1, compared to native cells. Conversely, the maturation of BACE1 was compromised under the stable expression of dominant–negative mutant PS1 overexpression. Immunoprecipitation assay showed that PS1 preferably interacts with proBACE1 rather than mature BACE1, indicating that PS1 can be directly involved in the maturation process of BACE1. Further, endogenous PS1 was immunoprecipitated with endogenous BACE1 in SH-SY5Y cells and mouse brain tissue. We conclude that PS1 is directly involved in the maturation of BACE1, thus possibly functioning as a regulator of both β- and γ-secretase in Aβ generation.
- 3 June 2004
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 6 (3) , 257-268
Proteome analysis of brain proteins in Alzheimer's disease: Subproteomics following sequentially extracted protein preparation
Quantitative proteome analysis of Alzheimer's disease (AD) brains was performed using two-dimensional (2-D) gels in order to find out the pathological protein expression in AD. We sequentially extracted brain proteins using two distinct sample soluti
- 3 June 2004
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 6 (3) , 257-268
Proteome analysis of brain proteins in Alzheimer's disease: Subproteomics following sequentially extracted protein preparation
Quantitative proteome analysis of Alzheimer's disease (AD) brains was performed using two-dimensional (2-D) gels in order to find out the pathological protein expression in AD. We sequentially extracted brain proteins using two distinct sample soluti
- Open Access
- 31 March 2004
- Published by The Nencki Institute of Experimental Biology, Polish Academy of Sciences in Acta Neurobiologiae Experimentalis
- Vol. 64 (1) , 99-105
Alzheimer's disease and acetylcholine receptors
Cholinergic abnormalities, alongside senile plaques, neurofibrillary tangles, and extensive neuronal loss, are the major characteristics in Alzheimer's disease (AD). Both nicotinic and muscarinic acetylcholine receptors are decreased in AD, and it has been shown that the reduction in the number of acetylcholine receptors precedes other pathologic changes. Anti-cholinergic drugs induce amnesia, which can be reversed by withdrawal of the medication. Inhibition of the down-regulation of acetylcholine is, therefore, a strategy for the treatment of AD because it could augment acetylcholine levels within synaptic clefts. In this context, acetylcholinesterase inhibitors, which improve cognitive functions, are currently approved for the treatment of AD. Stimulation of acetylcholine receptors, nicotinic or muscarinic, is another strategy; some drugs are currently under investigation, and reported to be effective. In addition, nicotinic stimulation exerts a neuroprotective effect, and reduces the amyloid burden. Cholinergic therapy may counter the symptoms and progress of AD.
- 31 March 2004
- Published by The Nencki Institute of Experimental Biology, Polish Academy of Sciences in Acta Neurobiologiae Experimentalis
- Vol. 64 (1) , 99-105
Open AccessAlzheimer's disease and acetylcholine receptors
Cholinergic abnormalities, alongside senile plaques, neurofibrillary tangles, and extensive neuronal loss, are the major characteristics in Alzheimer's disease (AD). Both nicotinic and muscarinic acetylcholine receptors are decreased in AD, and it has been shown that the reduction in the number of acetylcholine receptors precedes other pathologic changes. Anti-cholinergic drugs induce amnesia, which can be reversed by withdrawal of the medication. Inhibition of the down-regulation of acetylcholine is, therefore, a strategy for the treatment of AD because it could augment acetylcholine levels within synaptic clefts. In this context, acetylcholinesterase inhibitors, which improve cognitive functions, are currently approved for the treatment of AD. Stimulation of acetylcholine receptors, nicotinic or muscarinic, is another strategy; some drugs are currently under investigation, and reported to be effective. In addition, nicotinic stimulation exerts a neuroprotective effect, and reduces the amyloid burden. Cholinergic therapy may counter the symptoms and progress of AD.
- 20 August 2003
- Published by Wiley in Journal of Neuroscience Research
- Vol. 74 (2) , 184-191
Presenilin 1 is involved in maturation and trafficking of N‐cadherin to the plasma membrane
One pathological characteristic of Alzheimer's disease (AD) is extensive synapse loss. Presenilin 1 (PS1) is linked to the pathogenesis of early onset familial Alzheimer's disease (FAD) and is localized at the synapse, where it binds N‐cadherin and modulates its adhesive activity. To elucidate the role of the PS1/N‐cadherin interaction in synaptic contact, we established SH‐SY5Y cells stably expressing wild‐type (wt) PS1 and dominant‐negative (D385A) PS1. We show that the formation of cadherin‐based cell–cell contact among SH‐SY5Y cells stably expressing D385A PS1 was suppressed. Conversely, wt PS1 cells exhibited enhanced cell–cell contact and colony formation. Suppression of cell–cell contact in D385A cells was accompanied by an alteration in N‐cadherin subcellular localization; N‐cadherin was retained mainly in the endoplasmic reticulum (ER) and cell surface expression was reduced. We conclude that PS1 is essential for efficient trafficking of N‐cadherin from the ER to the plasma membrane. PS1‐mediated delivery of N‐cadherin to the plasma membrane is important for N‐cadherin to exert its physiological function, and it may control the state of cell–cell contact.
- 20 August 2003
- Published by Wiley in Journal of Neuroscience Research
- Vol. 74 (2) , 184-191
Presenilin 1 is involved in maturation and trafficking of N‐cadherin to the plasma membrane
One pathological characteristic of Alzheimer's disease (AD) is extensive synapse loss. Presenilin 1 (PS1) is linked to the pathogenesis of early onset familial Alzheimer's disease (FAD) and is localized at the synapse, where it binds N‐cadherin and modulates its adhesive activity. To elucidate the role of the PS1/N‐cadherin interaction in synaptic contact, we established SH‐SY5Y cells stably expressing wild‐type (wt) PS1 and dominant‐negative (D385A) PS1. We show that the formation of cadherin‐based cell–cell contact among SH‐SY5Y cells stably expressing D385A PS1 was suppressed. Conversely, wt PS1 cells exhibited enhanced cell–cell contact and colony formation. Suppression of cell–cell contact in D385A cells was accompanied by an alteration in N‐cadherin subcellular localization; N‐cadherin was retained mainly in the endoplasmic reticulum (ER) and cell surface expression was reduced. We conclude that PS1 is essential for efficient trafficking of N‐cadherin from the ER to the plasma membrane. PS1‐mediated delivery of N‐cadherin to the plasma membrane is important for N‐cadherin to exert its physiological function, and it may control the state of cell–cell contact.
- 1 August 2003
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 9 (8) , 360-365
Disease model: Parkinson's disease
- 1 August 2003
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 9 (8) , 360-365
Disease model: Parkinson's disease
- Open Access
- 1 April 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (14) , 12130-12134
The Role of the Presenilin-1 Homologue Gene sel-12 ofCaenorhabditis elegans in Apoptotic Activities
- 1 April 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (14) , 12130-12134
Open AccessThe Role of the Presenilin-1 Homologue Gene sel-12 ofCaenorhabditis elegans in Apoptotic Activities
- 1 January 2003
- Published by Springer Nature in Endocrine
- Vol. 21 (1) , 77-80
Estrogens and Parkinson Disease: Novel Approach for Neuroprotection
Epidemiologic studies revealed that the prevalence of Parkinson disease is higher in males than in females and that the progression of the disease might be rapid in males compared with females. The reason for the gender difference is unknown; however, estrogens may be involved. Many studies have revealed that estrogens provide neuroprotective effects and that the protective mechanisms include antioxidant property and upregulation of Bcl-2, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor (GDNF). Upregulation of Bcl-2 or GDNF is mediated by nonnuclear estrogen receptor (ER) in addition to transcription regulation by ER. To avoid undesirable effect of estrogens, several selective ER modulators, raloxifene and genistein are considered.
- 1 January 2003
- Published by Springer Nature in Endocrine
- Vol. 21 (1) , 77-80
Estrogens and Parkinson Disease: Novel Approach for Neuroprotection
Epidemiologic studies revealed that the prevalence of Parkinson disease is higher in males than in females and that the progression of the disease might be rapid in males compared with females. The reason for the gender difference is unknown; however, estrogens may be involved. Many studies have revealed that estrogens provide neuroprotective effects and that the protective mechanisms include antioxidant property and upregulation of Bcl-2, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor (GDNF). Upregulation of Bcl-2 or GDNF is mediated by nonnuclear estrogen receptor (ER) in addition to transcription regulation by ER. To avoid undesirable effect of estrogens, several selective ER modulators, raloxifene and genistein are considered.
- Open Access
- 1 January 2003
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 92 (2) , 115-123
Involvement of Wiskott-Aldrich Syndrome Protein Family Verprolin-Homologous Protein (WAVE) and Rac1 in the Phagocytosis of Amyloid-β(1 – 42) in Rat Microglia
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2003
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 92 (2) , 115-123
Open AccessInvolvement of Wiskott-Aldrich Syndrome Protein Family Verprolin-Homologous Protein (WAVE) and Rac1 in the Phagocytosis of Amyloid-β(1 – 42) in Rat Microglia
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 28 April 2002
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 4 (2) , 71-76
Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease
Since the loss of cholinergic neurons in the Alzheimer's disease (AD) brain was first reported, considerable evidence in vivo and in vitro has accumulated in support of the cholinergic hypothesis of AD. The hypothesis is greatly supported by the fact that the most promising drugs against AD are inhibitors of acetylcholinesterase (AChE). To identify the possible mutations and/or polymorphisms of neuronal nicotinic acetylcholine receptor (nAChR) genes related to the pathogenesis of sporadic AD, we have performed mutational analyses of the major neuronal nAChR genes (CHRNA3, 4, 7 and CHRNB2) expressed in central nervous system. Allelic analysis showed association of specific silent or intronic polymorphisms of the CHRNA3 and CHRNA4 genes and AD. Two novel missense point mutations, Ser413Leu in the CHRNA4 gene and Gln397Pro in the CHRNB2 gene, were identified in two different AD cases but were not found in other AD cases and controls. These findings suggested that genetic polymorphisms of the neuronal nAChR genes might be related to the pathogenesis of sporadic AD.
- 28 April 2002
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 4 (2) , 71-76
Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease
Since the loss of cholinergic neurons in the Alzheimer's disease (AD) brain was first reported, considerable evidence in vivo and in vitro has accumulated in support of the cholinergic hypothesis of AD. The hypothesis is greatly supported by the fact that the most promising drugs against AD are inhibitors of acetylcholinesterase (AChE). To identify the possible mutations and/or polymorphisms of neuronal nicotinic acetylcholine receptor (nAChR) genes related to the pathogenesis of sporadic AD, we have performed mutational analyses of the major neuronal nAChR genes (CHRNA3, 4, 7 and CHRNB2) expressed in central nervous system. Allelic analysis showed association of specific silent or intronic polymorphisms of the CHRNA3 and CHRNA4 genes and AD. Two novel missense point mutations, Ser413Leu in the CHRNA4 gene and Gln397Pro in the CHRNB2 gene, were identified in two different AD cases but were not found in other AD cases and controls. These findings suggested that genetic polymorphisms of the neuronal nAChR genes might be related to the pathogenesis of sporadic AD.
- 1 December 2001
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 289 (5) , 1063-1066
Differential Expression of Rat Brain Caspase Family Proteins during Development and Aging
- 1 December 2001
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 289 (5) , 1063-1066
Differential Expression of Rat Brain Caspase Family Proteins during Development and Aging